Sign in
Active, not recruitingPhase 2

Efficacy and tolerability of the combination of anifrolumab (300 mg IV) and phototherapy versus phototherapy in adults with progressive vitiligo

Key facts

Who runs it
Centre Hospitalier Universitaire De Bordeaux
Where
France5 sites in 1 countryChoose a country to see its sites
Status
Active, not recruiting
Phase
Phase 2
People taking part
48 people, planned
Started
27 Nov 2023
Expected to end
30 Jun 2027
Type of study
Interventional
Record updated
13 January 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Subject male or female aged ≥ 18 years and ≤ 65 years
  • Subject with body weight > or = 40kg
  • Diagnosis of non-segmental (symmetrical) vitiligo with a body surface area involved >5% excluding hands and feet
  • Active non-segmental vitiligo is defined by: • Non-segmental vitiligo with new patches or extension of old lesions during the last 6 months AND • Presence of hypochromic aspect under Wood’s lamp examination and/or perifollicular hypopigmentation under Wood’s lamp examination
  • Able to read, understand, and give documented (electronic or paper signature) informed consent
  • Affiliated or beneficiary of the French Social Security
  • Agree to discontinue the use of the following excluded medications/treatments for at least 4 weeks prior to randomization (Visit 2): phototherapy
  • Agree to discontinue the use of the following excluded medications/treatments for at least 4 weeks prior to randomization and throughout the study: systemic steroids, methotrexate, cyclosporine, mycophenolate mofetil, azathioprine
  • Agree to discontinue the use of the following excluded medications for at least 2 weeks prior to randomization and throughout the study: • TCS or topical immune modulators (e.g., tacrolimus or pimecrolimus) • Topical phosphodiesterase type 4 (PDE-4) inhibitor (crisaborole) • Topical JAK inhibitor (e.g., tofacitinib or ruxolitinib) and/or any other investigational topical treatments

Who cannot take part

  • Are currently experiencing or have a history of other concomitant skin conditions (e.g., psoriasis or lupus erythematosus) that would interfere with evaluations of the effect of study medication on vitiligo
  • Patients who are currently experiencing a skin infection that requires treatment, or who are currently being treated, with topical or systemic antibiotics. Note: Patients may not be rescreened until at least 4 weeks after the date of their previous screen failure and at least 2 weeks after resolution of the infection
  • Have any serious concomitant illness that is anticipated to require the use of systemic corticosteroids or otherwise interfere with study participation or require active frequent monitoring (e.g., unstable chronic asthma)
  • Current alcohol, drug, or chemical abuse
  • Patients with history of basal cell or squamous epithelial skin cancer or melanoma
  • Presence of significant uncontrolled neuropsychiatric disorder, are clinically judged by the investigator to be at risk for suicide
  • Segmental or mixed vitiligo

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To evaluate the efficacy of the combination of anifrolumab intravenous (IV) every four weeks + UVB TL01 (twice a week) by the evaluation of the percentage of skin repigmentation after 36 weeks of treatment using the VASI score in the experimental group receiving anifrolumab + UVB TL01.

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Efficacy and tolerance of the association of ANIFROLUMAB (300mg) IV every four weeks and phototherapy versus phototherapy in adults with progressive vitiligo: a randomized double blind prospective, non comparative Proof of Concept phase II study - VITANI
Record updated
13 January 2026